'We're good to go': MyoKardia clinches crucial PhIII win, boosting genetic approach to cardio R&D
MyoKardia said its lead drug has delivered a clean sweep in a Phase III trial, validating its groundbreaking idea for bringing precision medicine to cardiomyopathies and paving the way for an NDA filing early next year.
Consistency was the theme trumped by the top team in a conference call, where Marc Semigran, SVP of medical sciences, offered some more numbers on the primary endpoint and a slate of secondary endpoints beyond the stellar p-values in the release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.